Dupont Capital Management Corp grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 65.9% during the fourth quarter, HoldingsChannel reports. The firm owned 2,598 shares of the life sciences company’s stock after buying an additional 1,032 shares during the period. Dupont Capital Management Corp’s holdings in Illumina were worth $779,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Financial Enhancement Group LLC bought a new stake in Illumina in the third quarter valued at about $400,000. Nan Shan Life Insurance Co. Ltd. acquired a new stake in shares of Illumina during the 3rd quarter valued at $52,099,000. Handelsbanken Fonder AB acquired a new stake in Illumina during the 3rd quarter valued at $8,442,000. Hall Laurie J Trustee increased its stake in shares of Illumina by 61.8% in the third quarter. Hall Laurie J Trustee now owns 890 shares of the life sciences company’s stock worth $327,000 after acquiring an additional 340 shares during the last quarter. Finally, Pacer Advisors Inc. increased its stake in shares of Illumina by 18.2% in the third quarter. Pacer Advisors Inc. now owns 13,597 shares of the life sciences company’s stock worth $4,991,000 after acquiring an additional 2,092 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.
NASDAQ:ILMN opened at $293.52 on Thursday. The stock has a market capitalization of $43.44 billion, a PE ratio of 51.31, a price-to-earnings-growth ratio of 2.03 and a beta of 1.20. Illumina, Inc. has a 1-year low of $216.34 and a 1-year high of $372.61. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 0.23.
ILMN has been the subject of a number of recent analyst reports. UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and upped their price target for the company from $340.00 to $370.00 in a report on Thursday, January 3rd. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $355.00 price target for the company in a report on Tuesday, October 23rd. Bank of America reaffirmed a “buy” rating and issued a $355.00 price objective on shares of Illumina in a research note on Wednesday, January 30th. Morgan Stanley reduced their price target on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating on the stock in a research report on Monday, January 7th. Finally, Deutsche Bank cut shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 price objective on the stock. in a research report on Friday, January 25th. Five equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $346.40.
In other Illumina news, insider Francis A. Desouza sold 3,000 shares of Illumina stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $345.90, for a total value of $1,037,700.00. Following the transaction, the insider now owns 65,443 shares in the company, valued at $22,636,733.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Karin Eastham sold 5,000 shares of Illumina stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $294.08, for a total value of $1,470,400.00. Following the completion of the transaction, the director now owns 12,655 shares in the company, valued at approximately $3,721,582.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,947 shares of company stock valued at $11,026,616. 0.54% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Illumina, Inc. (ILMN) Shares Bought by Dupont Capital Management Corp” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://weekherald.com/2019/02/14/illumina-inc-ilmn-shares-bought-by-dupont-capital-management-corp.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Story: Systematic Risk and Investors
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.